Last reviewed · How we verify
NCT06814860: LH2004ME
Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents
trial in Classical Hodgkin Lymphoma in 36 participants. Completed in 31 October 2024.
23 May 2024
Quick facts
| Lead sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 36 |
| Start date | 7 February 2024 |
| Primary completion | 23 May 2024 |
| Estimated completion | 31 October 2024 |
| Sites | 1 location across Italy |
Conditions studied
- Classical Hodgkin Lymphoma — all drugs for Classical Hodgkin Lymphoma →
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →
Who can join
Adults 12 to 18, any sex, with Classical Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background. Classical Hodgkin's lymphoma (cHL) in adolescents between 15 and 18 years shows a higher disease-related mortality and the overall prognosis is worse than both children and adults. Objectives. To investigate the immune checkpoint inhibitors (ICPI) therapeutic targets and specific T-regulatory and cytotoxic T-cell subsets, in the subgroup of adolescent cHL patients and to investigate their prognostic power. Methods: Retrieved formalin-fixed paraffin-embedded (FFPE) of adolescent patients diagnosed with cHL with available clinical and tested by immunohistochemistry the immune checkpoint molecules CTLA-4, LAG-3, PD-1 and PDL1 and the biological markers FOXP3 and CD8.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06814860
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Classical Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06870487 — A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers · Phase 1 · active not recruiting
- NCT06848569 — Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study · Phase 2 · recruiting
- NCT06563245 — Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment · Phase 2, PHASE3 · recruiting
- NCT05934084 — Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · NA · recruiting
- NCT05900765 — A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma · Phase 2 · recruiting
Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials
Trials by the same sponsor.
- NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
- NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
- NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
- NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
- NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06814860 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06814860.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing